Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0% · short 2.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GELESIS HOLDINGS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
5 buysbar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| PureTech Health plc | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| PureTech Health LLC | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo | SEC |
| PureTech Health plc | BuyD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| PureTech Health plc | BuyD (derivative) | $15.1T | SEC |
| PureTech Health plc | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| PureTech Health plc | BuyD (derivative) | $25T | First in 12mo | SEC |
| PureTech Health plc | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| PureTech Health plc | BuyD (derivative) | $4T | First in 12mo | SEC |
| KUCHERLAPATI RAJU S | Buy | $3.1K | conv 22 | SEC |
| KUCHERLAPATI RAJU S | Buy | $41.4K | conv 41 | SEC |
| KUCHERLAPATI RAJU S | Buy | $48K | conv 27 | SEC |
| Sannino Alessandro | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sannino Alessandro | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chiquette Elaine | Award | n/a (No price was disclosed in the filing) | SEC |
| Chiquette Elaine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pass David A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zohar Yishai | Award | n/a (No price was disclosed in the filing) | SEC |
| Maltz Elliot | Award | n/a (No price was disclosed in the filing) | SEC |
| Zohar Yishai | Award | n/a (No price was disclosed in the filing) | SEC |
| Perks Dominic | Award | n/a (No price was disclosed in the filing) | SEC |
| Leider Harry L. | Award | n/a (No price was disclosed in the filing) | SEC |
| Maltz Elliot | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pass David A. | Award | n/a (No price was disclosed in the filing) | SEC |
| Pass David A. | Award | n/a (No price was disclosed in the filing) | SEC |
| Abraham David | Award | n/a (No price was disclosed in the filing) | SEC |